Rapporto sull’analisi delle dimensioni del mercato e delle quote del mercato degli anticorpi monoclonali | Previsioni 2031

  • Report Code : TIPRE00026641
  • Category : Biotechnology
  • Status : Published
  • No. of Pages : 163
Buy Now

Si prevede che il mercato degli anticorpi monoclonali raggiungerà i 243,05 miliardi di dollari entro il 2028, rispetto ai 111,01 miliardi di dollari del 2021; si prevede che crescerà a un CAGR dell'11,8% dal 2021 al 2028.

La crescente prevalenza di cancro e altre malattie croniche e un enorme aumento dei casi di COVID-19 in varie regioni sono i fattori chiave che alimentano la crescita del mercato. Secondo il World Cancer Research Fund e l’American Institute for Cancer, nel 2020 sono stati registrati circa 18,1 milioni di casi di cancro, di cui 9,3 milioni di casi negli uomini e 8,8 milioni di casi nelle donne. L'uso di anticorpi monoclonali nel trattamento di vari tipi di cancro è ancora in fase di sperimentazione di fase 2 e fase 3.

Approfondimenti strategici


È probabile che il Nord America continui a dominare il mercato degli anticorpi monoclonali nel periodo dal 2021 al 2028. Gli Stati Uniti detengono la quota maggiore del mercato in questa regione e si prevede che continueranno a essere un azionista dominante nel mercato durante il periodo di previsione. Secondo le statistiche pubblicate da Globocan 2020, negli Stati Uniti sono stati diagnosticati circa 1.806.590 nuovi casi di cancro e circa 606.520 persone sono morte a causa di questa malattia. Secondo un rapporto del Dipartimento del Commercio degli Stati Uniti, il suo National Institute of Standards and Technology (NIST) ha annunciato il finanziamento di 153 milioni di dollari all'Istituto nazionale per l'innovazione nella produzione biofarmaceutica. Inoltre, la FDA ha esteso il supporto per lo sviluppo di anticorpi monoclonali durante la prevalenza del COVID-19.

Regioni redditizie per il mercato degli anticorpi monoclonali

  ;

Approfondimenti di mercato

Il significativo aumento della prevalenza del cancro e di altre malattie croniche guida la crescita del mercato

Secondo l'American Cancer Society rapporto, a gennaio 2019 risiedevano negli Stati Uniti circa 16,9 milioni di persone con una storia di cancro. Entro gennaio 2030, si stima che la popolazione di sopravvissuti al cancro salirà a 22,1 milioni a causa della sola crescita e invecchiamento della popolazione. Pertanto, con la crescente prevalenza del cancro e di altre malattie croniche, è aumentata anche la domanda di farmaci biologici, come gli anticorpi monoclonali (mAB). Essendo i componenti principali di molti regimi terapeutici e trattamenti dal rapporto costo-efficacia, i farmaci biologici svolgono un ruolo chiave nel trattamento del cancro.

Approfondimenti basati sulla fonte

Basati alla fonte, il mercato degli anticorpi monoclonali è segmentato in murino, chimerico, umano e umanizzato. Si stima che il segmento umano rappresenterà la quota di mercato maggiore nel periodo 2021-2028. La crescita del mercato di questo segmento è attribuibile all'aumento dovuto all'integrazione di anticorpi monoclonali umani per il trattamento di vari tipi di malattie infettive. Ad esempio, Regeneron ha lanciato insieme il cocktail di anticorpi casirivimab e imdevimab approvati dalla FDA per l’uso nel COVID-19. Il farmaco ha ricevuto l'autorizzazione all'uso di emergenza (EUA) dalla FDA. È utilizzato per il trattamento della COVID-19 da lieve a moderata negli adulti e nei pazienti pediatrici di almeno 12 anni di età e di peso pari ad almeno 40 kg. Inoltre, un aumento del loro utilizzo in varie malattie croniche e l'impiego di tecnologie avanzate di ingegneria genetica sono tra i fattori significativi che guidano la crescita del segmento di mercato.

Mercato degli anticorpi monoclonali, per Fonte: 2020 e 2028

Approfondimenti basati sulle indicazioni

Basati su indicazione, cancro, malattie autoimmuni, malattie infiammatorie, malattie infettive, malattie microbiche e altre. Il segmento del cancro dominerà il mercato nei prossimi anni. I progressi relativi all’applicazione terapeutica degli anticorpi monoclonali hanno consentito la loro implementazione con successo nei trattamenti di vari tipi di cancro, come il cancro al seno, il cancro ai polmoni e il cancro del colon. I farmaci basati su questi anticorpi aiutano a segnalare le cellule tumorali, innescando la distruzione della membrana cellulare, bloccando gli inibitori del sistema immunitario e così via. La FDA, nel giugno 2020, ha approvato due farmaci: olaparib e rucaparib per il trattamento del cancro alla prostata. Il farmaco è particolarmente efficace tra gli uomini affetti da condizioni di cancro alla prostata che si sono diffuse o hanno metastatizzato e che hanno smesso di rispondere ai trattamenti ormonali standard, ad esempio, condizioni patologiche resistenti alla castrazione.

Utente finale- Approfondimenti basati

In base all'utente finale, il mercato degli anticorpi monoclonali è segmentato in ospedali, istituti di ricerca e altri. Il segmento ospedaliero detiene la quota di mercato maggiore grazie alla crescente adozione dei mAB come linea di trattamento preferita, in particolare per il trattamento del cancro.

 

Le aziende che operano nel mercato degli anticorpi monoclonali adottano la strategia di innovazione del prodotto per soddisfare le richieste in continua evoluzione dei clienti in tutto il mondo, consentendo loro anche di mantenere il proprio marchio nel mercato globale.

Mercato degli anticorpi monoclonali: segmentazione< /h3>

In base alla fonte, il mercato degli anticorpi monoclonali è segmentato in umano, umanizzato, chimerico e murino. In base al metodo di produzione, il mercato è segmentato in in vitro e in vivo. Il mercato degli anticorpi monoclonali, per indicazione, è ulteriormente segmentato come cancro, malattie autoimmuni, malattie infettive, malattie infiammatorie, malattie microbiche e altri. Per applicazione, il mercato è suddiviso in applicazioni terapeutiche, applicazioni diagnostiche e applicazioni di ricerca. Inoltre, in base all'utente finale, il mercato è segmentato in ospedali, altri e istituti di ricerca.

Mercato degli anticorpi monoclonali: per geografia

  • Nord America
    • Stati Uniti
    • Canada
    • Messico
  • Europa
    • Francia
    • Germania
    • Italia
    • Regno Unito
    • Spagna
    • Resto d'Europa
    • Asia Pacifico (APAC)
      • Cina
      • India
      • Corea del Sud
      • Giappone
      • Australia
      • Resto dell'APAC
    • Medio Oriente e Africa (MEA)
      • Sudafrica
      • Arabia Saudita
      • Emirati Arabi Uniti
      • Resto del MEA
    • America centrale e meridionale (SCAM)
      • Brasile
      • Argentina
      • Resto delle truffe

    Profili aziendali
    • Novartis AG
    • Pfizer Inc.
    • GlaxoSmithKline plc
    • Amgen, Inc
    • Daiichi Sankyo Company, Limitato
    • F. Hoffmann-La Roche AG
    • AstraZeneca
    • Elli Lily and Company
    • Bayer AG
    • Bristol-Myers Squibb Company
    • < /ul> 

Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


What is the regional market scenario of the monoclonal antibodies market?

Global monoclonal antibodies market is segmented by region into North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America. In North America, the U.S. is the largest market for monoclonal antibodies market. The US is estimated to hold the largest share in the monoclonal antibodies market during the forecast period. The presence of top players and favorable regulations related to product approvals coupled with commercializing new products are the contributing factors for the regional growth. Additionally, the increasing number of R&D activities is the key factor responsible for the Asia-Pacific regional growth for monoclonal antibodies accounting fastest growth of the region during the coming years.

Who are the key players in the monoclonal antibodies market?

Novartis AG, Pfizer, Inc., GlaxoSmithKline Plc, Amgen, Inc., Daiichi Sankyo Company, Limited, F.Hoffmann-La Roche AG, AstraZeneca, Elli Lilly and Company, Bayer AG, Bristol-Myers Squibb Company are among the leading companies operating in the global monoclonal antibodies market

Which production method segment held the largest revenue (US$ Mn) in the monoclonal antibodies market?

The in vitro segment dominated the global monoclonal antibodies market and accounted for the largest revenue of 75,044.50 Mn in 2021.

What is meant by the monoclonal antibodies market?

Food and Drug Administration (FDA) defines monoclonal antibodies as immunoglobulin molecules that are secreted from a population of identical cells. They are homogenous in structure and binding specificity. These are used as multifunctional components for the immune system. They facilitate numerous cellular and humoral reactions to a variety of antigens, which include host and foreign substances.

What are the driving factors for the monoclonal antibodies market across the globe?

Significant rise in the cancer and chronic diseases is one of the most significant factors responsible for the overall market growth.

Which segment led the monoclonal antibodies market?

Based on source, human segment took the forefront lead in the worldwide market by accounting largest share in 2020 and is expected to continue to do so till the forecast period.

The List of Companies - Monoclonal Antibody Market

  1. Novartis AG
  2. Pfizer Inc.
  3. GlaxoSmithKline plc
  4. Amgen, Inc
  5. Daiichi Sankyo Company, Limited
  6. F. Hoffmann-La Roche AG
  7. AstraZeneca
  8. Elli Lilly and Company
  9. Bayer AG
  10. Bristol-Myers Squibb Company

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports